Flesinoxan

Flesinoxan
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 4-fluoro-N-(2-{4-[(2S)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl}ethyl)benzamide;
CAS Number	98206-10-1;
PubChem CID	57347;
IUPHAR/BPS	1;
ChemSpider	51700;
UNII	3V574S89E1;
KEGG	D02568;
ChEMBL	ChEMBL1742477;
Chemical and physical data
Formula	C22H26FN3O4
Molar mass	415.465 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)F)C3=C4C(=CC=C3)O[C@H](CO4)CO;
	InChI InChI=1S/C22H26FN3O4/c23-17-6-4-16(5-7-17)22(28)24-8-9-25-10-12-26(13-11-25)19-2-1-3-20-21(19)29-15-18(14-27)30-20/h1-7,18,27H,8-15H2,(H,24,28)/t18-/m0/s1; Key:NYSDRDDQELAVKP-SFHVURJKSA-N;

Flesinoxan (DU-29,373) is a potent and selective 5-HT_1A receptor partial/near-full agonist of the phenylpiperazine class. Originally developed as a potential antihypertensive drug, flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests. As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability. However, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further.

In patients, flesinoxan enhances REM sleep latency, decreases body temperature, and increases ACTH, cortisol, prolactin, and growth hormone secretion.